Journal of Internal Medicine Concepts & Practice >
Application of lipid-modulating drugs in treatment of non-alcoholic fatty liver disease
ZHANG Ruixiang, SUN Shuoshuo, WEI Xiao, et al . Application of lipid-modulating drugs in treatment of non-alcoholic fatty liver disease[J]. Journal of Internal Medicine Concepts & Practice, 2023 , 18(03) : 215 -220 . DOI: 10.16138/j.1673-6087.2023.03.017
| [1] | Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224. |
| [2] | Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression[J]. Cell Mol Life Sci, 2019, 76(1): 99-128. |
| [3] | Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease[J]. J Hepatol, 2020, 73(1): 202-209. |
| [4] | Sanyal AJ. Past, present and future perspectives in non-alcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6): 377-386. |
| [5] | Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24(7): 908-922. |
| [6] | Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease[J]. Cell, 2021, 184(10): 2537-2564. |
| [7] | Doumas M, Imprialos K, Dimakopoulou A, et al. The role of statins in the management of nonalcoholic fatty liver disease[J]. Curr Pharm Des, 2018, 24(38): 4587-4592. |
| [8] | Athyros VG, Boutari C, Stavropoulos K, et al. Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk[J]. Curr Vasc Pharmacol, 2018, 16(3): 246-253. |
| [9] | Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals[J]. J Hepatol, 2015, 63(3): 705-712. |
| [10] | Ahsan F, Oliveri F, Goud HK, et al. Pleiotropic effects of statins in the light of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. Cureus, 2020, 12(9): e10446. |
| [11] | Ioannou GN, van Rooyen DM, Savard C, et al. Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH[J]. J Lipid Res, 2015, 56(2): 277-285. |
| [12] | Yokohama K, Fukunishi S, Ii M, et al. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice[J]. Int J Mol Med, 2016, 38(5): 1499-1506. |
| [13] | Francque S, Szabo G, Abdelmalek MF, et al. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(1): 24-39. |
| [14] | Park HS, Jang JE, Ko MS, et al. Statins increase mitochondrial and peroxisomal fatty acid oxidation in the liver and prevent non-alcoholic steatohepatitis in mice[J]. Diabetes Metab J, 2016, 40(5): 376-385. |
| [15] | Guixé-Muntet S, de Mesquita FC, Vila S, et al. Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury[J]. J Hepatol, 2017, 66(1): 86-94. |
| [16] | Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins[J]. Gut, 2020, 69(5): 953-962. |
| [17] | Cho Y, Rhee H, Kim YE, et al. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease[J]. BMC Med, 2022, 20(1): 93. |
| [18] | Noto D, Petta S, Giammanco A, et al. Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): a double-blind randomised placebo-controlled trial[J]. Nutr Metab Cardiovasc Dis, 2022, 32(5): 1288-1291. |
| [19] | Muraoka T, Aoki K, Iwasaki T, et al. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet[J]. Metabolism, 2011, 60(5):617-628. |
| [20] | Lee DH, Han DH, Nam KT, et al. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis[J]. Free Radic Biol Med, 2016, 99: 520-532. |
| [21] | Chang E, Kim L, Park SE, et al. Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats[J]. World J Gastroenterol, 2015, 21(25): 7754-7763. |
| [22] | Kim SH, Kim G, Han DH, et al. Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition[J]. Autophagy, 2017, 13(10): 1767-1781. |
| [23] | Kessoku T, Kobayashi T, Ozaki A, et al. Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease[J]. BMJ Open, 2020, 10(9): e037961. |
| [24] | Hartmann P, Duan Y, Miyamoto Y, et al. Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice[J]. Hepatol Int, 2022, 16(2): 359-370. |
| [25] | El-Haggar SM, Mostafa TM. Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease[J]. Hepatol Int, 2015, 9(3): 471-479. |
| [26] | Sasaki Y, Asahiyama M, Tanaka T, et al. Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content[J]. Sci Rep, 2020, 10(1): 7818. |
| [27] | Honda Y, Kessoku T, Ogawa Y, et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis[J]. Sci Rep, 2017, 7: 42477. |
| [28] | Parmeggiani B, Grings M, da Rosa-Junior NT, et al. Bezafibrate prevents glycine-induced increase of antioxidant enzyme activities in rat striatum[J]. Mol Neurobiol, 2019, 56(1): 29-38. |
| [29] | Boyraz M, Pirgon ?, Dündar B, et al. Long-term treatment with n-3 polyunsaturated fatty acids as a monotherapy in children with nonalcoholic fatty liver disease[J]. J Clin Res Pediatr Endocrinol, 2015, 7(2): 121-127. |
| [30] | Li YH, Yang LH, Sha KH, et al. Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis[J]. World J Gastroenterol, 2015, 21(22): 7008-7013. |
| [31] | Jung TW, Kim HC, Abd El-Aty AM, et al. Maresin 1 attenuates NAFLD by suppression of endoplasmic reticulum stress via AMPK-SERCA2b pathway[J]. J Biol Chem, 2018, 293(11): 3981-3988. |
| [32] | Laiglesia LM, Lorente-Cebrián S, Martínez-Fernández L, et al. Maresin 1 mitigates liver steatosis in ob/ob and diet-induced obese mice[J]. Int J Obes (Lond), 2018, 42(3): 572-579. |
| [33] | Gnoni A, Giudetti AM. Dietary long-chain unsaturated fatty acids acutely and differently reduce the activities of lipogenic enzymes and of citrate carrier in rat liver[J]. J Physiol Biochem, 2016, 72(3): 485-494. |
| [34] | Cho L, Rocco M, Colquhoun D, et al. Clinical profile of statin intolerance in the phase 3 GAUSS-2 study[J]. Cardiovasc Drugs Ther, 2016, 30(3): 297-304. |
| [35] | Paquette M, Gauthier D, Chamberland A, et al. Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis[J]. Clin Biochem, 2020, 77: 20-25. |
| [36] | Rimbert A, Smati S, Dijk W, et al. Genetic inhibition of PCSK9 and liver function[J]. JAMA Cardiol, 2021, 6(3): 353-354. |
| [37] | Scicali R, Di Pino A, Urbano F, et al. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: a single lipid center real-world experience[J]. Nutr Metab Cardiovasc Dis, 2021, 31(3): 869-879. |
| [38] | Ioannou GN, Lee SP, Linsley PS, et al. PCSK9 deletion promotes murine nonalcoholic steatohepatitis and hepatic carcinogenesis[J]. Hepatol Commun, 2022, 6(4): 780-794. |
| [39] | Fogacci F, Ferri N, Toth PP, et al. Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials[J]. Drugs, 2019, 79(7): 751-766. |
| [40] | Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease[J]. Cell, 2021, 184(10):2537-2564. |
/
| 〈 |
|
〉 |
